Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), shared a post on X:
“Impressive results from ESMO25!
Dr. Jun Guo presented RC48-C016 ph3 Disitamab Vedotin + Toripalimab in 1L HER2+ mUC bladder cancer vs chemo PFS: 13.1 vs 6.5 mo (HR 0.36), OS: 31.5 vs 16.9 mo (HR 0.54). Gr ≥3 TRAE 55% vs 87%)
A potential new SOC!”
You Can Also Read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
